Merck could exceed $67 billion in sales in 2026
Published
The American pharmaceutical company Merck could reach sales of over $67 billion in 2026. This estimate is based on the strong results from the third quarter of the year, according to Forbes Romania.
The most important driver of growth was the oncology division, meaning the field that deals with the treatment of cancer. Merck reported a solid quarter in this area, which plays an important role in the company's business.
The Merck Animal Health division, which produces medicines and vaccines for animals, had sales of $1.7 billion. This amount represents a 4% increase compared with the previous year.
In conclusion, Merck appears to be having a stable performance this year. For complete details on the financial results, readers can consult the company's official report.
Sources: Forbes Romania
More Romania news
- Romania's Forests Are Monitored by Satellite, Video Cameras and LiDAR Technology
- Romania did not ask the European Commission for help before the 2024 elections. What happened on TikTok
- Romanian fintech companies look for expansion opportunities in Poland
- Drones manufactured in Romania with technology tested on the Ukrainian front: a 200 million euro project
- Romania and Greece discuss fiscal cooperation and joint economic projects
- Luca Niculescu has taken office as prime minister, and S&P has not downgraded Romania's rating
- Marta Kos: Moldova's and Ukraine's integration into the EU depends on each country's results
- Parliament to Vote on Tuesday on New Members of the Boards of Directors of the Public Television and Public Radio